NCT03184584View on ClinicalTrials.gov

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions
Alström Syndrome
Interventions
DRUG

PBI-4050

Four 200 mg capsules (800 mg total) administered orally, once daily

Trial Locations (1)

B15 2PR

University Hospitals Birmingham NHS Foundation Trus, Birmingham

Sponsors
All Listed Sponsors
lead

Liminal BioSciences Ltd.

INDUSTRY

NCT03184584 - Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome | Biotech Hunter | Biotech Hunter